Episode Details

This episode reviews updated AAP recommendations for RSV prevention in infants and high-risk children entering a second RSV season, phase 3 data suggesting TP53 mutation status may help identify patients with EGFR-mutated advanced non–small cell lung cancer who benefit from adding chemotherapy to osimertinib, and results from two phase 3 trials showing that the IL-33–targeting biologic tozorakimab reduced COPD exacerbations in patients who remained at risk despite standard inhaled therapy.